Main
TALAPRO-2, prostate cancer, prostate
PROSTATE CANCER, PROSTATE
Recent approvals of new treatments have led to improved outcomes for patients with advanced prostate cancerPreclinical evidence suggests interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and PARP, providing a rationale for their co-inhibitionMonotherapy with the PARP inhibitor talazoparib (1 mg per day) showed durable antitumor activity and a favorable benefit–risk profile in patients with heavily pretreated mCRPC with HRR gene alterations in the phase 2, TALAPRO-1 studyA recent analysis of the all-comers population of TALAPRO-2 revealed significant improvement in radiographic progression-free survival (rPFS) for talazoparib plus enzalutamide compared with enzalutamide as standard of care (hazard ratio (HR), 0.63; 95% confidence interval (CI), 0.51 to 0.78; 